CN107106556B - 用于治疗精神分裂症的缓释制剂中阿立哌唑衍生物的结晶方法 - Google Patents

用于治疗精神分裂症的缓释制剂中阿立哌唑衍生物的结晶方法 Download PDF

Info

Publication number
CN107106556B
CN107106556B CN201580057857.XA CN201580057857A CN107106556B CN 107106556 B CN107106556 B CN 107106556B CN 201580057857 A CN201580057857 A CN 201580057857A CN 107106556 B CN107106556 B CN 107106556B
Authority
CN
China
Prior art keywords
temperature
mixture
aripiprazole
solvent
crystalline particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580057857.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN107106556A (zh
Inventor
维尔弗雷多·小莫拉勒斯
塔雷克·A·蔡丹
雷纳托·A·查雷拉
斯蒂文·G·赖特
贾森·M·佩里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Inc
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Inc filed Critical Alkermes Inc
Priority to CN202010375290.3A priority Critical patent/CN111454207B/zh
Publication of CN107106556A publication Critical patent/CN107106556A/zh
Application granted granted Critical
Publication of CN107106556B publication Critical patent/CN107106556B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
CN201580057857.XA 2014-08-25 2015-08-24 用于治疗精神分裂症的缓释制剂中阿立哌唑衍生物的结晶方法 Active CN107106556B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010375290.3A CN111454207B (zh) 2014-08-25 2015-08-24 用于治疗精神分裂症的缓释制剂中阿立哌唑衍生物的结晶方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462041341P 2014-08-25 2014-08-25
US62/041,341 2014-08-25
PCT/US2015/046525 WO2016032950A1 (en) 2014-08-25 2015-08-24 Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010375290.3A Division CN111454207B (zh) 2014-08-25 2015-08-24 用于治疗精神分裂症的缓释制剂中阿立哌唑衍生物的结晶方法

Publications (2)

Publication Number Publication Date
CN107106556A CN107106556A (zh) 2017-08-29
CN107106556B true CN107106556B (zh) 2020-06-05

Family

ID=55347322

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010375290.3A Active CN111454207B (zh) 2014-08-25 2015-08-24 用于治疗精神分裂症的缓释制剂中阿立哌唑衍生物的结晶方法
CN201580057857.XA Active CN107106556B (zh) 2014-08-25 2015-08-24 用于治疗精神分裂症的缓释制剂中阿立哌唑衍生物的结晶方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010375290.3A Active CN111454207B (zh) 2014-08-25 2015-08-24 用于治疗精神分裂症的缓释制剂中阿立哌唑衍生物的结晶方法

Country Status (20)

Country Link
US (5) US10064859B2 (enExample)
EP (2) EP3185867B1 (enExample)
JP (2) JP6591546B2 (enExample)
CN (2) CN111454207B (enExample)
AU (2) AU2015306910B2 (enExample)
CA (1) CA2959329C (enExample)
CY (1) CY1124058T1 (enExample)
DK (1) DK3185867T3 (enExample)
ES (2) ES2862098T3 (enExample)
HR (1) HRP20210551T1 (enExample)
HU (1) HUE054641T2 (enExample)
IL (1) IL250661B (enExample)
LT (1) LT3185867T (enExample)
MA (2) MA40480B1 (enExample)
PL (1) PL3185867T3 (enExample)
PT (1) PT3185867T (enExample)
RS (1) RS61709B1 (enExample)
SI (1) SI3185867T1 (enExample)
SM (1) SMT202100212T1 (enExample)
WO (1) WO2016032950A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2792149T3 (es) 2012-09-19 2020-11-10 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
HUE054641T2 (hu) * 2014-08-25 2021-09-28 Alkermes Pharma Ireland Ltd Skizofrénia kezelésére szolgáló elnyújtott felszabadulású készítményekben lévõ aripiprazol származékok kristályosítási eljárása
US20180155290A1 (en) * 2015-05-08 2018-06-07 Davuluri Ramamohan Rao Improved Process for the Preparation of Aripiprazole with Reduced Particle Size
WO2018104953A1 (en) * 2016-12-07 2018-06-14 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 7-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]butoxy}-2oxo-3,4-dihydro-2h-quinolin-1-yl)methyl dodecanoate
EP3658540B1 (en) 2017-07-28 2021-12-01 Interquim, S.A. Process for the preparation of aripiprazole lauroxil
CN110218209B (zh) * 2018-03-02 2022-09-30 上海现代药物制剂工程研究中心有限公司 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN113105389B (zh) * 2021-04-16 2022-04-08 江苏海洋大学 一种阿立哌唑药物共晶及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
CN1817882A (zh) * 2001-09-25 2006-08-16 大塚制药株式会社 低吸湿性阿立哌唑药物及其制备方法
CN103561746A (zh) * 2011-03-18 2014-02-05 奥克梅斯制药爱尔兰有限公司 包含脱水山梨糖醇酯的药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
MXPA06004489A (es) * 2003-10-23 2006-06-20 Otsuka Pharma Co Ltd Formulacion y metodo de aripiprazol inyectable esteril de liberacion controlada.
KR102163196B1 (ko) 2007-12-19 2020-10-12 얀센 파마슈티카 엔.브이. 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법
US20110003823A1 (en) 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
HUE033442T2 (en) * 2009-06-25 2017-11-28 Alkermes Pharma Ireland Ltd Heterocyclic compounds for the treatment of neurological and psychological disorders
WO2012077134A1 (en) * 2010-12-07 2012-06-14 Ind-Swift Laboratories Limted Process for preparing aripiprazole polymorphs
JP5968909B2 (ja) * 2011-01-07 2016-08-10 ネオダイン バイオサイエンシーズ， インコーポレイテッド 創傷または皮膚処置デバイスおよび方法
CA2867121C (en) * 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
ES2792149T3 (es) * 2012-09-19 2020-11-10 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada
HUE054641T2 (hu) * 2014-08-25 2021-09-28 Alkermes Pharma Ireland Ltd Skizofrénia kezelésére szolgáló elnyújtott felszabadulású készítményekben lévõ aripiprazol származékok kristályosítási eljárása

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
CN1817882A (zh) * 2001-09-25 2006-08-16 大塚制药株式会社 低吸湿性阿立哌唑药物及其制备方法
CN103561746A (zh) * 2011-03-18 2014-02-05 奥克梅斯制药爱尔兰有限公司 包含脱水山梨糖醇酯的药物组合物

Also Published As

Publication number Publication date
US20200108063A1 (en) 2020-04-09
ES2862098T3 (es) 2021-10-07
SI3185867T1 (sl) 2021-08-31
NZ729479A (en) 2021-03-26
ES2994850T3 (en) 2025-02-03
US20210205302A1 (en) 2021-07-08
US20240245676A1 (en) 2024-07-25
CA2959329C (en) 2023-06-27
MA55917A (fr) 2022-03-16
IL250661A0 (en) 2017-04-30
CN107106556A (zh) 2017-08-29
AU2015306910A1 (en) 2017-03-16
MA40480B1 (fr) 2021-08-31
AU2020264303B2 (en) 2022-10-13
PL3185867T3 (pl) 2021-11-22
SMT202100212T1 (it) 2021-07-12
EP3865476A1 (en) 2021-08-18
HUE054641T2 (hu) 2021-09-28
JP6591546B2 (ja) 2019-10-16
IL250661B (en) 2020-04-30
EP3865476B1 (en) 2024-08-14
PT3185867T (pt) 2021-04-12
AU2020264303A1 (en) 2020-11-26
US10064859B2 (en) 2018-09-04
WO2016032950A1 (en) 2016-03-03
CY1124058T1 (el) 2022-05-27
CN111454207A (zh) 2020-07-28
EP3185867A1 (en) 2017-07-05
LT3185867T (lt) 2021-06-10
AU2015306910B2 (en) 2020-11-19
US11883394B2 (en) 2024-01-30
CA2959329A1 (en) 2016-03-03
HRP20210551T1 (hr) 2021-08-20
EP3185867B1 (en) 2021-01-13
US10478434B2 (en) 2019-11-19
CN111454207B (zh) 2024-10-18
AU2015306910A8 (en) 2020-11-19
JP2019210296A (ja) 2019-12-12
EP3185867A4 (en) 2018-01-24
DK3185867T3 (da) 2021-03-15
JP2017526747A (ja) 2017-09-14
US20160051546A1 (en) 2016-02-25
US10973816B2 (en) 2021-04-13
RS61709B1 (sr) 2021-05-31
US20190015408A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
CN107106556B (zh) 用于治疗精神分裂症的缓释制剂中阿立哌唑衍生物的结晶方法
JP4376518B2 (ja) サブミクロン粒子の懸濁物を調製する方法
CN1761454A (zh) 小颗粒的制备方法
CN1870987A (zh) 制备紫杉醇亚微米颗粒的方法
CN1750811A (zh) 在冷冻水基质中包括颗粒的稳定组合物
CN108864069A (zh) 一种利伐沙班微粒及其制备方法与应用
HK40057525A (en) Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
HK40057525B (en) Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
NZ729479B2 (en) Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
HK1246636A1 (en) Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
HK1246636B (en) Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
JP2012214525A (ja) ポリ乳酸微粒子含有凍結乾燥組成物の製造方法
CN1812767A (zh) 一种制备药用有效成分晶体的方法以及由该方法获得的晶体和晶体在药剂制备中的应用
Ditzinger Supersaturating oral delivery systems of poorly water-soluble compounds produced by hot melt extrusion
Park et al. Solid Dispersion of an HIV Protease Inhibitor
Desai et al. FORMULATION AND EVALUATION OF MICROPARTICLES FORMED BY AMPHIPHILLIC CRYSTALLIZATION TECHNIQUE: OPTIMIZATION OF PROCESS PARAMETER
HK1090287A (en) Process for production of crystals of a medicinally effective ingredient, crystals obtained thereby and their use in pharmaceutical preparations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant